Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 420 Phase 1 Single-Arm Study in Japan
jRCT2080224797Phase 1Completed
- Sponsor
- Amgen
- Start
- Jul 2019
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of pacanalotamab, sponsored by Amgen. Primary endpoint: Dose-limiting toxicities (DLTs). Started Jul 2019; status: completed.
02
Drugs
pacanalotamab
Beyond the preview
Go deeper on jRCT2080224797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224797.